Antigestagenically active steroids with a fluorinated 17alpha-alkyl chain
    4.
    发明申请
    Antigestagenically active steroids with a fluorinated 17alpha-alkyl chain 失效
    具有氟化17α-烷基链的抗发生活性类固醇

    公开(公告)号:US20050080060A1

    公开(公告)日:2005-04-14

    申请号:US10948652

    申请日:2004-09-24

    摘要: This invention describes the new 17α-fluoroalkyl steroids of general formula I in which R1 stands for a methyl or ethyl group, R2 stands for a radical of formula CnFmHo, whereby n is 2, 3, 4, 5 or 6, m>1 and m+o=2n+1, R3 stands for a free, etherified or esterified hydroxy group, R4 and R5 each stand for a hydrogen atom, or together for an additional bond or a methylene group, St stands for a steroidal ABC-ring system of partial formula A, B or C in which R6 means a hydrogen atom, a straight-chain C1-C4 alkyl group or branched C3-C4 alkyl group or a halogen atom, R7 means a hydrogen atom, a straight-chain C1-C4 alkyl group or a branched C3-C4 alkyl group, or if St stands for a steroidal ABC-ring system A or B, in addition R6 and R7 together can mean an additional bond, X means an oxygen atom, a hydroxyimino grouping ═N—OH or two hydrogen atoms, R8 means a radical Y or an aryl radical that is optionally substituted in several places with a group Y, whereby Y is a hydrogen atom, a halogen atom, an —OH, —NO2, —N3, —CN, —NR9aR9b, —NHSO2R9, —CO2R9, C1-C10 alkoxy, C1-C10 alkanoyloxy, benzoyloxy, C1-C10 alkanoyl, C1-C10 hydroxyalkyl or benzoyl group, and R9a and R9b are the same or different and in the same way as R9 represent a hydrogen atom or a C1-C10 alkyl group, and for —NR9aR9b radicals, as well as their physiologically compatible salts with acids and for —CO2R9 radicals with R9 meaning hydrogen, as well as their physiologically compatible salts with bases. The new compounds have an extraordinarily strong antigestagenic action and are suitable for the production of pharmaceutical preparations.

    摘要翻译: 本发明描述了通式I的新型17α-氟烷基类固醇,其中R 1代表甲基或乙基,R 2代表式C n F m H o基团,其中n为2,3,4,5或 6,m> 1和m + o = 2n + 1,R 3表示游离的醚化或酯化的羟基,R 4和R 5各自代表氢原子,或一起代表另外的 键或亚甲基,St代表部分式A,B或C的甾族ABC-环体系,其中R 6表示氢原子,直链C 1 -C 4烷基或支链C 3 -C 4烷基 或卤素原子,R 7表示氢原子,直链C 1 -C 4烷基或支链C 3 -C 4烷基,或者如果St代表甾族ABC环系统A或B,另外R R 6和R 7一起可以表示另外的键,X表示氧原子,羟基亚氨基= N-OH或两个氢原子,R 8表示任意取代的基团Y或芳基 几个地方有一个Y组,Y是一个 氢原子,卤素原子,-OH,-NO 2,-N 3,-CN,-NR 9a R 9b,-NHSO 2 R 9,-CO 2 R 9,C 1 -C 10烷氧基,C 1 -C 10 烷酰氧基,苯甲酰氧基,C 1 -C 10烷酰基,C 1 -C 10羟烷基或苯甲酰基,R 9a和R 9b相同或不同,并且R 9表示氢原子或C1- C10烷基,对于-NR 9a R 9b基团,以及它们与酸的生理上相容的盐以及具有R 9表示氢的-CO 2 R 9基团,以及它们与 基地 新化合物具有非常强的抗前体作用,适用于制备药物制剂。

    14.beta.-H-, 14-and 15-En-11.beta.-aryl-4-oestrenes
    7.
    发明授权
    14.beta.-H-, 14-and 15-En-11.beta.-aryl-4-oestrenes 失效
    14β-H,14和15-En-11β-芳基-4-盎司

    公开(公告)号:US5426102A

    公开(公告)日:1995-06-20

    申请号:US81269

    申请日:1993-06-22

    摘要: Novel compounds of the general formula I ##STR1## and the pharmacologically tolerable addition salts thereof with acids are described, in which eitherIa) R.sup.11 represents a hydrogen atom in the .beta.-configuration and each of R.sup.12 and R.sup.13 represents a hydrogen atom, orIb) R.sup.11 represents a hydrogen atom in the .beta.-configuration and R.sup.12 and R.sup.13 together represent a second bond, orIc) R.sup.11 and R.sup.12 together represent a second bond and R.sup.13 represents a hydrogen atom, orId) R.sup.11 represents a hydrogen atom in the .alpha.-configuration and R.sup.12 and R.sup.13 together represent a second bond,and in Ia), Ib), Ic) or Id)X represents an oxygen atom, the hydroxyimino grouping >N.about.OH or two hydrogen atoms,R.sup.1 represents a hydrogen atom or a methyl group,R.sup.2 represents a hydroxy group, a C.sub.1 -C.sub.10 -alkoxy group or a C.sub.1 -C.sub.10 -acyloxy group, andR.sup.3 and R.sup.4 have the meanings customary for competitive progesterone antagonists specified in the description.The invention relates also to processes for the preparation of the novel compounds, to pharmaceutical compositions containing those compounds, to their use for the manufacture of medicaments, and to the novel intermediates required for the process.The novel compounds have a strong affinity for the gestagen receptor and exhibit pronounced antigestagenic and also antiglucocorticoid, antimineralocorticoid and antiandrogenic properties.

    摘要翻译: PCT No.PCT / EP91 / 02494 371日期:1993年6月22日 102(e)日期1993年11月1日PCT 1991年12月21日PCT PCT。 出版物WO92 / 11278 描述了通式I的新型化合物(Ⅰ)及其与酸的药理学上可以忍受的加成盐,其中Ia)R11表示β-构型中的氢原子, R 12和R 13表示氢原子,或Ib)R 11表示β构型中的氢原子,R 12和R 13一起表示第二键,或者Ic)R 11和R 12一起表示第二键,R 13表示氢原子,或 Id)R11表示α-构型中的氢原子,R 12和R 13一起表示第二键,并且在Ia),Ib),Ic)或Id)中X表示氧原子,羟基亚氨基> N不同OH或两个 氢原子,R 1表示氢原子或甲基,R 2表示羟基,C 1 -C 10 - 烷氧基或C 1 -C 10 - 酰氧基,R 3和R 4具有常规用于在 描述。 本发明还涉及制备新化合物的方法,含有这些化合物的药物组合物,其用于制备药物的方法以及该方法所需的新型中间体。 新化合物对于孕激素受体具有强烈的亲和力,并且具有显着的抗原成分和抗糖皮质激素,抗皮质激素和抗雄激素的特性。

    D-homo-(16-ene)-11.beta.-aryl-4-estrenes, process for their production
as well as their use as pharmaceutical agents
    9.
    发明授权
    D-homo-(16-ene)-11.beta.-aryl-4-estrenes, process for their production as well as their use as pharmaceutical agents 失效
    D-均聚(16-烯)-11β-芳基-4-雌酮,其制备方法以及作为药剂的用途

    公开(公告)号:US5519027A

    公开(公告)日:1996-05-21

    申请号:US78326

    申请日:1994-02-25

    CPC分类号: C07J63/008

    摘要: New D-homo-(16-ene)-11.beta.-aryl-4-estrenes of general formula I ##STR1## as well as their pharmaceutically compatible addition salts with acids are described in whichX stands for an oxygen atom, the hydroxyimino grouping >N.about.OH or two hydrogen atoms,R.sup.1 stands for a hydrogen atom or a methyl group,R.sup.2 stands for an hydroxy group, a C.sub.1 -C.sub.10 alkoxy or C.sub.1 -C.sub.10 acyloxy group,R.sup.11 stands for a fluorine, chlorine or bromine atom, and then R.sup.12 and R.sup.13 together mean an additional bond orR.sup.11 stands for a straight-chain or branched-chain C.sub.1 -C.sub.4 -alkyl radical or a hydrogen atom, and then R.sup.12 and R.sup.13 each mean a hydrogen atom or together mean an additional bond,and R.sup.3 and R.sup.4 have the usual meanings indicated in the description for competitive progesterone antagonists.The invention further relates to a process for the production of new compounds, pharmaceutical preparations containing these compounds, their use for the production of pharmaceutical agents as well as the new intermediate products necessary for the process.The new compounds have a strong affinity to the gestagen receptor and show strong antigestagen as well as antiglucocorticoid, antimineral corticoid and antiandrogenic properties.

    摘要翻译: PCT No.PCT / EP91 / 02495 371日期1994年2月25日 102(e)1994年2月25日PCT PCT 1991年12月21日PCT公布。 出版物WO92 / 11279 日期:1992年7月9日。通式I(I)的新型D-均 - (16-烯)-11β-芳基-4-雌酮及其与酸的药学上相容的加成盐描述于其中 X表示氧原子,羟基亚氨基> N不同OH或两个氢原子,R1表示氢原子或甲基,R2表示羟基,C1-C10烷氧基或C1-C10酰氧基,R11 代表氟,氯或溴原子,然后R 12和R 13一起表示另外的键或R 11表示直链或支链的C 1 -C 4烷基或氢原子,则R 12和R 13各自表示 氢原子或一起表示另外的键,并且R3和R4具有在竞争性孕酮拮抗剂的描述中指出的通常含义。 本发明还涉及生产新化合物的方法,含有这些化合物的药物制剂,其用于生产药物的用途以及该方法所需的新的中间产物。 新化合物对孕激素受体具有强烈的亲和力,并显示出强的抗老化,以及抗糖皮质激素,抗癫痫皮质激素和抗雄激素的特性。